MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597807 | Name: Pimobendan, (-)-

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pimobendan, (-)- is an oral calcium-sensitizing inodilator.

Chemical Structure

Pimobendan, (-)-
Pimobendan, (-)-
CAS#118428-37-8

Theoretical Analysis

MedKoo Cat#: 597807

Name: Pimobendan, (-)-

CAS#: 118428-37-8

Chemical Formula: C19H18N4O2

Exact Mass: 334.1430

Molecular Weight: 334.37

Elemental Analysis: C, 68.25; H, 5.43; N, 16.76; O, 9.57

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Pimobendan, (-)-; Pimobendan;
IUPAC/Chemical Name
6-(2-(4-methoxyphenyl)-1H-benzo[d]imidazol-5-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
InChi Key
GLBJJMFZWDBELO-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)
SMILES Code
O=C1CC(C)C(C2=CC=C3C(N=C(C4=CC=C(OC)C=C4)N3)=C2)=NN1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 334.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med. 2008 Sep-Oct;22(5):1124-35. doi: 10.1111/j.1939-1676.2008.0150.x. Epub 2008 Jul 11. PubMed PMID: 18638016. 2: Fuentes VL, Corcoran B, French A, Schober KE, Kleemann R, Justus C. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Intern Med. 2002 May-Jun;16(3):255-61. PubMed PMID: 12041654. 3: O'Grady MR, Minors SL, O'Sullivan ML, Horne R. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy. J Vet Intern Med. 2008 Jul-Aug;22(4):897-904. doi: 10.1111/j.1939-1676.2008.0116.x. PubMed PMID: 18537880. 4: Hagemeijer F. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. Eur Heart J. 1993 Apr;14(4):551-66. Review. PubMed PMID: 8472722. 5: Ichihara K, Abiko Y. The effect of pimobendan on myocardial mechanical function and metabolism in dogs: comparison with dobutamine. J Pharm Pharmacol. 1991 Aug;43(8):583-8. PubMed PMID: 1681075. 6: Kato K. Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan. Cardiology. 1997;88 Suppl 2:28-36. PubMed PMID: 9142433. 7: Permanetter B, Sebening H, Hartmann F, Baumann G, Lutilsky L. Effect of intravenous pimobendan (UDCG 115 BS) on hemodynamics and left ventricular volumes in idiopathic dilative cardiomyopathy. J Cardiovasc Pharmacol. 1989 Dec;14(6):803-9. PubMed PMID: 2481765. 8: Solaro RJ, Fujino K, Sperelakis N. The positive inotropic effect of pimobendan involves stereospecific increases in the calcium sensitivity of cardiac myofilaments. J Cardiovasc Pharmacol. 1989;14 Suppl 2:S7-12. PubMed PMID: 2478795. 9: Lombard CW, Jöns O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006 Jul-Aug;42(4):249-61. PubMed PMID: 16822763. 10: Kanno N, Kuse H, Kawasaki M, Hara A, Kano R, Sasaki Y. Effects of pimobendan for mitral valve regurgitation in dogs. J Vet Med Sci. 2007 Apr;69(4):373-7. PubMed PMID: 17485924. 11: Fitton A, Brogden RN. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. Drugs Aging. 1994 May;4(5):417-41. Review. PubMed PMID: 8043944. 12: Chu KM, Hu OY, Shieh SM. Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects. Drug Metab Dispos. 1999 Jun;27(6):701-9. PubMed PMID: 10348800. 13: Lee JA, Ruegg JC, Allen DG. Effects of pimobendan, a novel inotropic agent, on intracellular calcium and tension in isolated ferret ventricular muscle. Clin Sci (Lond). 1989 Jun;76(6):609-18. PubMed PMID: 2544344. 14: Hata K, Goto Y, Futaki S, Ohgoshi Y, Yaku H, Kawaguchi O, Takasago T, Saeki A, Taylor TW, Nishioka T, et al. Mechanoenergetic effects of pimobendan in canine left ventricles. Comparison with dobutamine. Circulation. 1992 Oct;86(4):1291-301. PubMed PMID: 1394935. 15: Chen CH, Nakaya Y, Minami K, Kubo M. Effects of pimobendan and its active metabolite, UD-CG 212 Cl, on Ca2+-activated K+ channels in vascular smooth-muscle cells. J Cardiovasc Pharmacol. 1997 Dec;30(6):739-43. PubMed PMID: 9436812. 16: Maruyama M, Takamura M, Takata S, Murai H, Usui S, Furusho H, Sakagami S, Yuasa T, Shimakura A, Kaneko S. Effect of pimobendan on cardiopulmonary baroreflex control of sympathetic nerve activity in healthy young men. Auton Neurosci. 2005 Oct 30;122(1-2):100-6. Epub 2005 Sep 30. PubMed PMID: 16199209. 17: van Meel JC, Diederen W. Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharmacol. 1989;14 Suppl 2:S1-6. PubMed PMID: 2478784. 18: Kitzen JM, Lynch JJ, Driscoll EM, Lucchesi BR. Cardiac electrophysiologic and hemodynamic activity of pimobendan (UD-CG 115 BS), a new inotropic agent. J Pharmacol Exp Ther. 1988 Mar;244(3):929-39. PubMed PMID: 3252039. 19: Chu KM, Shieh SM, Hu OY. Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese. Eur J Clin Pharmacol. 1995;47(6):537-42. PubMed PMID: 7768258. 20: Pahernik SA, Schmid J, Sauter T, Schildberg FW, Koebe HG. Metabolism of pimobendan in long-term human hepatocyte culture: in vivo-in vitro comparison. Xenobiotica. 1995 Aug;25(8):811-23. PubMed PMID: 8779223.

View History

PIM-IN-72

PIM-IN-72